Health Care

Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.

ACADIA Pharmaceuticals stock analysis: ACAD hits a 2-year high on strong profitability, but a rich EV/EBITDA multiple keeps the model at Hold.

Beam Therapeutics stock analysis: BEAM nears its 2-year high as revenue drops 94% YoY, driving the model’s signal to Sell.

Recursion Pharmaceuticals stock analysis: RXRX nears its two-year low as revenue drops 60.1% TTM and cash burn continues despite a strong balance sheet.

Generate Biomedicines, Inc. stock analysis: GENB hits a 2-year high on thin revenue, deep losses, and a still-unrated valuation signal.

Legend Biotech Corporation stock analysis: 51.9% TTM revenue growth, near two-year lows, Hold signal on thin margins and no usable P/E.

Parabilis Medicines, Inc. stock analysis: shares hit a two-year high, but no P/E or P/B means the model can’t issue a Buy/Hold/Sell call.